Telisotuzumab Vedotin Clinical Trials (2026): 8 Studies for Non-Small Cell Lung Cancer & Non Small Cell Lung Cancer

Where to Participate: All Telisotuzumab Vedotin Trial Sites in the U.S. (53 sites across 23 states)

Every actively recruiting Telisotuzumab Vedotintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Telisotuzumab Vedotin clinical trials at a glance: phase × recruitment status

Recruiting Telisotuzumab Vedotin clinical trials (3)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Telisotuzumab Vedotin clinical trials by indication

Telisotuzumab Vedotin pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Telisotuzumab Vedotin trials (2)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT06093503withdrawnStudy of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
• NCT05513703terminatedA Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

All Telisotuzumab Vedotin trials (8)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Telisotuzumab Vedotin clinical trials: frequently asked questions

How many Telisotuzumab Vedotin clinical trials are there?

8 Telisotuzumab Vedotin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.

Are Telisotuzumab Vedotin clinical trials recruiting in 2026?

Yes — 3 Telisotuzumab Vedotin trials are actively recruiting in 2026, with 53 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Telisotuzumab Vedotin being studied for?

Telisotuzumab Vedotin is being studied for Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, Advanced Solid Tumors Cancer, Lung Non-Small Cell Carcinoma, Non-small Cell Lung Cancer and 1 more. The trials are grouped by indication on this page.

What phase is Telisotuzumab Vedotin in?

Telisotuzumab Vedotin clinical trials span 2 Phase 3, 4 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Telisotuzumab Vedotin clinical trials?

The lead sponsor across the most Telisotuzumab Vedotin trials is AbbVie, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Telisotuzumab Vedotinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.